New Board Member for Siegfried

Published: Jan 11, 2013

Zofingen, 11 January 2013 -- At the Shareholders’ Meeting scheduled for 18 April 2013, the Board of Directors of Siegfried Holding AG (SIX: SFZN) will propose the appointment to the Board of Colin Bond, Chief Financial Officer of Evotec AG.

Colin Bond, 52, is a citizen of Great Britain and Switzerland. In 2010, he joined Hamburg- based Evotec AG as group Chief Financial Officer and member of the management board. The company is listed on the Frankfurt Stock Exchange as part of TecDax and provides a wide range of research and development services in the field of pharmaceutical ingredients. Following career stations as a pharmacist, chartered accountant and management consult- ant, he worked for 25 years as Chief Financial Officer for several international companies in various industries, of which 11 years for Great Lakes Chemical Corporation, today Chemtura, a US-based global specialty chemicals company.

Colin Bond holds a university degree in pharmacy from the University of Aston, Birmingham, and a MBA degree from London Business School.

Gilbert Achermann, Chairman of Siegfried’s Board of Directors: “We are very happy to pro- pose to our Board such a convincing entrepreneur as Colin Bond. He will represent a valua- ble addition to the Board thanks to his profound experience in the finance sector and in the pharmaceutical industry, his proven capacity for strategic thinking, and his international con- nections.”

For further information:

Peter Gehler, Head Corporate Center

Tel. +41 (0)62 746 11 44

Mobile +41 (079) 416 41 16

Fax +41 (0)62 746 11 03

Siegfried Holding AG

Untere Brühlstrasse 4

CH-4800 Zofingen

About Siegfried

The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Malta and the USA. At the end of 2011, Siegfried reported annual sales of CHF 328 million and employs at the time being approximately 800 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingre- dients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.

Cautionary Statements Regarding Forward-looking Statements

This press release may contain forward-looking statements based on current assumptions and forecasts made by Siegfried Group management and other information currently available to the Siegfried Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Siegfried Holding AG does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to conform them to future events or developments.

Back to news